Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 22 September 2006:
Vol. 313. no. 5794, pp. 1785 - 1787
DOI: 10.1126/science.1127592
Prev | Table of Contents | Next

Reports

Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors

Yuval Shaked,1* Alessia Ciarrocchi,2* Marcela Franco,1 Christina R. Lee,1 Shan Man,1 Alison M. Cheung,3 Daniel J. Hicklin,4 David Chaplin,5 F. Stuart Foster,3 Robert Benezra,2 Robert S. Kerbel1{dagger}

The contribution of bone marrow–derived circulating endothelial progenitor cells (CEPs) to tumor angiogenesis has been controversial, primarily because of their low numbers in blood vessels of untreated tumors. We show that treatment of tumor-bearing mice with vascular disrupting agents (VDAs) leads to an acute mobilization of CEPs, which home to the viable tumor rim that characteristically remains after such therapy. Disruption of this CEP spike by antiangiogenic drugs or by genetic manipulation resulted in marked reductions in tumor rim size and blood flow as well as enhanced VDA antitumor activity. These findings also provide a mechanistic rationale for the enhanced efficacy of VDAs when combined with antiangiogenic drugs.

1 Department of Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5, Canada.
2 Program of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
3 Department of Imaging Research, Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5, Canada.
4 ImClone Systems, 180 Varick Street, 7th Floor, New York, NY 10014, USA.
5 OXiGENE Inc., 230 Third Avenue, Waltham, MA 02451, USA.

* These authors contributed equally to this work.

{dagger} To whom correspondence should be addressed. E-mail: robert.kerbel{at}sri.utoronto.ca

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger.
G. J. Madlambayan, J. M. Butler, K. Hosaka, M. Jorgensen, D. Fu, S. M. Guthrie, A. K. Shenoy, A. Brank, K. J. Russell, J. Otero, et al. (2009)
Blood 114, 4310-4319
   Abstract »    Full Text »    PDF »
Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.
L. G. Daenen, Y. Shaked, S. Man, P. Xu, E. E. Voest, R. M. Hoffman, D. J. Chaplin, and R. S. Kerbel (2009)
Mol. Cancer Ther. 8, 2872-2881
   Abstract »    Full Text »    PDF »
Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents.
Y. Shaked, T. Tang, J. Woloszynek, L. G. Daenen, S. Man, P. Xu, S.-R. Cai, J. M. Arbeit, E. E. Voest, D. J. Chaplin, et al. (2009)
Cancer Res. 69, 7524-7528
   Abstract »    Full Text »    PDF »
Glioma Tumor Stem-Like Cells Promote Tumor Angiogenesis and Vasculogenesis via Vascular Endothelial Growth Factor and Stromal-Derived Factor 1.
C. Folkins, Y. Shaked, S. Man, T. Tang, C. R. Lee, Z. Zhu, R. M. Hoffman, and R. S. Kerbel (2009)
Cancer Res. 69, 7243-7251
   Abstract »    Full Text »    PDF »
Guiding the Optimal Translation of New Cancer Treatments From Canine to Human Cancer Patients.
C. Khanna, C. London, D. Vail, C. Mazcko, and S. Hirschfeld (2009)
Clin. Cancer Res. 15, 5671-5677
   Abstract »    Full Text »    PDF »
High Levels of Circulating VEGFR2+ Bone Marrow-Derived Progenitor Cells Correlate with Metastatic Disease in Patients with Pediatric Solid Malignancies.
M. Taylor, J. Rossler, B. Geoerger, A. Laplanche, O. Hartmann, G. Vassal, and F. Farace (2009)
Clin. Cancer Res. 15, 4561-4571
   Abstract »    Full Text »    PDF »
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
A. Rapisarda, M. Hollingshead, B. Uranchimeg, C. A. Bonomi, S. D. Borgel, J. P. Carter, B. Gehrs, M. Raffeld, R. J. Kinders, R. Parchment, et al. (2009)
Mol. Cancer Ther. 8, 1867-1877
   Abstract »    Full Text »    PDF »
White Adipose Tissue Cells Are Recruited by Experimental Tumors and Promote Cancer Progression in Mouse Models.
Y. Zhang, A. Daquinag, D. O. Traktuev, F. Amaya-Manzanares, P. J. Simmons, K. L. March, R. Pasqualini, W. Arap, and M. G. Kolonin (2009)
Cancer Res. 69, 5259-5266
   Abstract »    Full Text »    PDF »
Nitric Oxide Synthase Inhibition Enhances the Tumor Vascular-Damaging Effects of Combretastatin A-4 3-O-Phosphate at Clinically Relevant Doses.
G. M. Tozer, V. E. Prise, G. Lewis, S. Xie, I. Wilson, and S. A. Hill (2009)
Clin. Cancer Res. 15, 3781-3790
   Abstract »    Full Text »    PDF »
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma.
J. Ruan, K. Hajjar, S. Rafii, and J. P. Leonard (2009)
Ann. Onc. 20, 413-424
   Abstract »    Full Text »    PDF »
Granulocyte Macrophage Colony-Stimulating Factor Inhibits Breast Cancer Growth and Metastasis by Invoking an Anti-Angiogenic Program in Tumor-Educated Macrophages.
T. D. Eubank, R. D. Roberts, M. Khan, J. M. Curry, G. J. Nuovo, P. Kuppusamy, and C. B. Marsh (2009)
Cancer Res. 69, 2133-2140
   Abstract »    Full Text »    PDF »
Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands.
Y. Cao (2009)
Science Signaling 2, re1
   Abstract »    Full Text »    PDF »
Dominant Effect of Antiangiogenesis in Combination Therapy Involving Cyclophosphamide and Axitinib.
J. Ma and D. J. Waxman (2009)
Clin. Cancer Res. 15, 578-588
   Abstract »    Full Text »    PDF »
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.
J. Ma and D. J. Waxman (2008)
Mol. Cancer Ther. 7, 3670-3684
   Abstract »    Full Text »    PDF »
Tumour vascular disrupting agents: combating treatment resistance.
G M Tozer, C Kanthou, G Lewis, V E Prise, B Vojnovic, and S A Hill (2008)
Br. J. Radiol. 81, S12-S20
   Abstract »    Full Text »    PDF »
The renin-angiotensin system and malignancy.
E. I. Ager, J. Neo, and C. Christophi (2008)
Carcinogenesis 29, 1675-1684
   Abstract »    Full Text »    PDF »
Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248.
R. G. Bagley, C. Rouleau, T. St. Martin, P. Boutin, W. Weber, M. Ruzek, N. Honma, M. Nacht, S. Shankara, S. Kataoka, et al. (2008)
Mol. Cancer Ther. 7, 2536-2546
   Abstract »    Full Text »    PDF »
Tumor Angiogenesis.
R. S. Kerbel (2008)
N. Engl. J. Med. 358, 2039-2049
   Full Text »    PDF »
Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth.
S. Purhonen, J. Palm, D. Rossi, N. Kaskenpaa, I. Rajantie, S. Yla-Herttuala, K. Alitalo, I. L. Weissman, and P. Salven (2008)
PNAS 105, 6620-6625
   Abstract »    Full Text »    PDF »
Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform-Producing Tumors.
G. M. Tozer, S. Akerman, N. A. Cross, P. R. Barber, M. A. Bjorndahl, O. Greco, S. Harris, S. A. Hill, D. J. Honess, C. R. Ireson, et al. (2008)
Cancer Res. 68, 2301-2311
   Abstract »    Full Text »    PDF »
Equilibrium between Host and Cancer Caused by Effector T Cells Killing Tumor Stroma.
B. Zhang, Y. Zhang, N. A. Bowerman, A. Schietinger, Y.-X. Fu, D. M. Kranz, D. A. Rowley, and H. Schreiber (2008)
Cancer Res. 68, 1563-1571
   Abstract »    Full Text »    PDF »
Tissue Inhibitor of Metalloproteinase-3 via Oncolytic Herpesvirus Inhibits Tumor Growth and Vascular Progenitors.
Y. Y. Mahller, S. S. Vaikunth, M. C. Ripberger, W. H. Baird, Y. Saeki, J. A. Cancelas, T. M. Crombleholme, and T. P. Cripe (2008)
Cancer Res. 68, 1170-1179
   Abstract »    Full Text »    PDF »
Induction of Cancer Metastasis by Cyclophosphamide Pretreatment of Host Mice: An Opposite Effect of Chemotherapy.
K. Yamauchi, M. Yang, K. Hayashi, P. Jiang, N. Yamamoto, H. Tsuchiya, K. Tomita, A. R. Moossa, M. Bouvet, and R. M. Hoffman (2008)
Cancer Res. 68, 516-520
   Abstract »    Full Text »    PDF »
ID genes mediate tumor reinitiation during breast cancer lung metastasis.
G. P. Gupta, J. Perk, S. Acharyya, P. de Candia, V. Mittal, K. Todorova-Manova, W. L. Gerald, E. Brogi, R. Benezra, and J. Massague (2007)
PNAS 104, 19506-19511
   Abstract »    Full Text »    PDF »
Suppression of Ewing's Sarcoma Tumor Growth, Tumor Vessel Formation, and Vasculogenesis Following Anti Vascular Endothelial Growth Factor Receptor-2 Therapy.
Z. Zhou, M. F. Bolontrade, K. Reddy, X. Duan, H. Guan, L. Yu, D. J. Hicklin, and E. S. Kleinerman (2007)
Clin. Cancer Res. 13, 4867-4873
   Abstract »    Full Text »    PDF »
Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells.
F Farace, C Massard, E Borghi, J-M Bidart, and J-C Soria (2007)
Ann. Onc. 18, 1421-1422
   Full Text »    PDF »
Antiangiogenic Strategies on Defense: On the Possibility of Blocking Rebounds by the Tumor Vasculature after Chemotherapy.
Y. Shaked and R. S. Kerbel (2007)
Cancer Res. 67, 7055-7058
   Abstract »    Full Text »    PDF »
Combination Chemotherapy Including Combretastatin A4 Phosphate and Paclitaxel Is Effective against Anaplastic Thyroid Cancer in a Nude Mouse Xenograft Model.
S.-C. J. Yeung, M. She, H. Yang, J. Pan, L. Sun, and D. Chaplin (2007)
J. Clin. Endocrinol. Metab. 92, 2902-2909
   Abstract »    Full Text »    PDF »
Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization.
D. J. Nolan, A. Ciarrocchi, A. S. Mellick, J. S. Jaggi, K. Bambino, S. Gupta, E. Heikamp, M. R. McDevitt, D. A. Scheinberg, R. Benezra, et al. (2007)
Genes & Dev. 21, 1546-1558
   Abstract »    Full Text »    PDF »
Tumor Angiogenesis Promoted by Ex vivo Differentiated Endothelial Progenitor Cells Is Effectively Inhibited by an Angiogenesis Inhibitor, TK1-2.
H.-K. Oh, J.-M. Ha, E. O, B. H. Lee, S. K. Lee, B.-S. Shim, Y.-K. Hong, and Y. A. Joe (2007)
Cancer Res. 67, 4851-4859
   Abstract »    Full Text »    PDF »
Biomarkers in Gastrointestinal Stromal Tumor: Should We Equate Blood-Based Pharmacodynamics with Tumor Biology and Clinical Outcomes?.
J. C. McAuliffe and J. C. Trent (2007)
Clin. Cancer Res. 13, 2535-2536
   Full Text »    PDF »
Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients.
C. Igreja, M. Courinha, A. S. Cachaco, T. Pereira, J. Cabecadas, M. G. da Silva, and S. Dias (2007)
Haematologica 92, 469-477
   Abstract »    Full Text »    PDF »
Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy.
S. Senan and E. F. Smit (2007)
Oncologist 12, 465-477
   Abstract »    Full Text »    PDF »
Biomarkers for Monitoring Antiangiogenic Therapy.
R. S. Bhatt, P. Seth, and V. P. Sukhatme (2007)
Clin. Cancer Res. 13, 777s-780s
   Abstract »    Full Text »    PDF »
Reassessment of Id1 Protein Expression in Human Mammary, Prostate, and Bladder Cancers Using a Monospecific Rabbit Monoclonal Anti-Id1 Antibody..
J. Perk, I. Gil-Bazo, Y. Chin, P. de Candia, J. J.S. Chen, Y. Zhao, S. Chao, W. Cheong, Y. Ke, H. Al-Ahmadie, et al. (2006)
Cancer Res. 66, 10870-10877
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)